These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37329878)

  • 21. Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease).
    Dulz S; Schwering C; Wildner J; Spartalis C; Schuettauf F; Bartsch U; Wibbeler E; Nickel M; Spitzer MS; Atiskova Y; Schulz A
    Br J Ophthalmol; 2023 Oct; 107(10):1478-1483. PubMed ID: 35772852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment.
    Iwan K; Patel N; Heslegrave A; Borisova M; Lee L; Bower R; Mole SE; Mills PB; Zetterberg H; Mills K; Gissen P; Heywood WE
    F1000Res; 2021; 10():614. PubMed ID: 35106137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2).
    Gutić M; Milosavljević MN; Safiye T; Milidrag A; Jankovic SM
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):561-570. PubMed ID: 36994735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MRI in CLN2 disease patients: Subtle features that support an early diagnosis.
    Aydın K; Havali C; Kartal A; Serdaroğlu A; Haspolat Ş
    Eur J Paediatr Neurol; 2020 Sep; 28():228-236. PubMed ID: 32855042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerliponase Alfa: First Global Approval.
    Markham A
    Drugs; 2017 Jul; 77(11):1247-1249. PubMed ID: 28589525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of the "Hamburg Best Practice Guidelines for ICV-Enzyme Replacement therapy (ERT) in CLN2 Disease" Based on 6 Years Treatment Experience in 48 Patients.
    Schwering C; Kammler G; Wibbeler E; Christner M; Knobloch JK; Nickel M; Denecke J; Baehr M; Schulz A
    J Child Neurol; 2021 Jul; 36(8):635-641. PubMed ID: 33543660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease).
    Katz ML; Coates JR; Sibigtroth CM; Taylor JD; Carpentier M; Young WM; Wininger FA; Kennedy D; Vuillemenot BR; O'Neill CA
    J Neurosci Res; 2014 Nov; 92(11):1591-8. PubMed ID: 24938720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2.
    Lewis G; Morrill AM; Conway-Allen SL; Kim B
    J Child Neurol; 2020 Apr; 35(5):348-353. PubMed ID: 31884868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Visual perception and macular integrity in non-classical CLN2 disease.
    Atiskova Y; Wildner J; Wibbeler E; Nickel M; Spitzer MS; Schwering C; Schulz A; Dulz S
    Graefes Arch Clin Exp Ophthalmol; 2022 Nov; 260(11):3693-3700. PubMed ID: 35652945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration.
    Kim A; Grover A; Hammon K; de Hart G; Slasor P; Cherukuri A; Ajayi T; Jacoby D; Schulz A; Specchio N; de Los Reyes E; Gissen P; Henshaw JW
    Clin Transl Sci; 2021 Mar; 14(2):635-644. PubMed ID: 33202105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management Strategies for CLN2 Disease.
    Williams RE; Adams HR; Blohm M; Cohen-Pfeffer JL; de Los Reyes E; Denecke J; Drago K; Fairhurst C; Frazier M; Guelbert N; Kiss S; Kofler A; Lawson JA; Lehwald L; Leung MA; Mikhaylova S; Mink JW; Nickel M; Shediac R; Sims K; Specchio N; Topcu M; von Löbbecke I; West A; Zernikow B; Schulz A
    Pediatr Neurol; 2017 Apr; 69():102-112. PubMed ID: 28335910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring concurrent validity of the CLN2 Clinical Rating Scale: Comparison to PedsQL using cerliponase alfa clinical trial data.
    Specchio N; Gissen P; de Los Reyes E; Olaye A; Camp C; Curteis T; Griffiths A; Butt T; Cohen-Pfeffer J; Slasor P; Sisic Z; Jain M; Schulz A
    PLoS One; 2024; 19(5):e0302382. PubMed ID: 38776275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravitreal enzyme replacement inhibits progression of retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis.
    Whiting REH; Robinson Kick G; Ota-Kuroki J; Lim S; Castaner LJ; Jensen CA; Kowal J; Nguyen A; Corado C; O'Neill CA; Katz ML
    Exp Eye Res; 2020 Sep; 198():108135. PubMed ID: 32634395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early Symptoms and Treatment Outcomes in Neuronal Ceroid Lipofuscinosis Type 2: Croatian Experience.
    Radić Nišević J; Kolić I; Kostanjski M; Kovačević F; Prpić I
    J Pers Med; 2024 Jul; 14(8):. PubMed ID: 39201975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cynomolgus macaque model of neuronal ceroid lipofuscinosis type 2 disease.
    Munesue Y; Ageyama N; Kimura N; Takahashi I; Nakayama S; Okabayashi S; Katakai Y; Koie H; Yagami KI; Ishii K; Tamaoka A; Yasutomi Y; Shimozawa N
    Exp Neurol; 2023 May; 363():114381. PubMed ID: 36918063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value of genetic testing for pediatric epilepsy: Driving earlier diagnosis of ceroid lipofuscinosis type 2 Batten disease.
    Leal-Pardinas F; Truty R; McKnight DA; Johnson B; Morales A; Bristow SL; Yar Pang T; Cohen-Pfeffer J; Izzo E; Sankar R; Koh S; Wirrell EC; Millichap JJ; Aradhya S
    Epilepsia; 2022 Jul; 63(7):e68-e73. PubMed ID: 35474188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease.
    Gardner E; Bailey M; Schulz A; Aristorena M; Miller N; Mole SE
    Hum Mutat; 2019 Nov; 40(11):1924-1938. PubMed ID: 31283065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multifocal retinopathy in Dachshunds with CLN2 neuronal ceroid lipofuscinosis.
    Whiting RE; Pearce JW; Castaner LJ; Jensen CA; Katz RJ; Gilliam DH; Katz ML
    Exp Eye Res; 2015 May; 134():123-32. PubMed ID: 25697710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolution of Movement Disorders in Patients With CLN2-Batten Disease Treated With Enzyme Replacement Therapy.
    Spaull R; Soo AK; Batzios S; Footitt E; Whiteley R; Mink JW; Carr L; Gissen P; Kurian MA
    Neurology; 2024 Aug; 103(3):e209615. PubMed ID: 38976822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Untargeted Metabolite Profiling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2, Batten Disease).
    Sindelar M; Dyke JP; Deeb RS; Sondhi D; Kaminsky SM; Kosofsky BE; Ballon DJ; Crystal RG; Gross SS
    Sci Rep; 2018 Oct; 8(1):15229. PubMed ID: 30323181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.